PMN vs CPSH Comparison

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

CPS Technologies Corp designs, manufactures, and sells high-performance material solutions for customers across various markets, including transportation, energy, automotive, electronics, telecommunications, aerospace, and defense. The company develops and applies proprietary expertise in metal matrix composites (MMCs), which are engineered materials combining metals and ceramics to achieve enhanced performance properties. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers. The majority of the company's revenue is derived from the sale of its products in the United States of America.